期刊
ARCHIVES OF NEUROLOGY
卷 58, 期 7, 页码 1081-1086出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archneur.58.7.1081
关键词
-
资金
- NIMH NIH HHS [R01 MH59708] Funding Source: Medline
Objective: To examine the relationship between depression, treatment of depression, and interferon gamma (IFN-gamma) production by peripheral blood mononuclear cells in patients with comorbid diagnoses of relapsing-remitting multiple sclerosis (MS) and major depressive disorder. Design: A randomized comparative outcome trial of three 16-week treatments for depression. Assessments were conducted at baseline, week 8, and treatment cessation. Setting: An academic outpatient treatment and clinical research center. Patients: Fourteen patients who met the criteria for relapsing-remitting MS and major depressive disorder. Interventions: Individual cognitive behavioral therapy, group psychotherapy, or sertraline therapy. Main Outcome Measures: Depression was assessed using the Beck Depression Inventory. Interferon gamma production by peripheral blood mononuclear cells was measured following stimulation with OKT3 or recombinant human myelin oligodendrocyte glycoprotein (MOG). Variability in immune assays was controlled using 8 nondepressed healthy subjects who were enrolled at times corresponding with the enrollment of MS patients. Results: Results of the Beck Depression Inventory were significantly related to IFN-gamma production stimulated with OKT3 or MOG at baseline (P less than or equal to .03 for all). Level of depression, OKT3-stimulated IFN-gamma production, and MOG-stimulated IFN-gamma production all declined significantly over the 16-week treatment period (P less than or equal to .03 for all). Among controls, there were no significant changes over time in OKT3-or MOG-stimulated IFN-gamma, or in depression (P greater than or equal to .25 for all). Conclusions: These findings suggest that the production of the proinflammatory cytokine IFN-gamma by autoaggressive T cells in relapsing-remitting MS is related to depression and that treatment of depression may decrease IFN-gamma production. Thus, treatment of depression may provide a novel disease-modifying therapeutic strategy as well as a symptomatic treatment for patients with MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据